Suzhou VencuBio Ltd. was established in February 2021, guided by the unmet clinical needs, and is committed to the research and development of innovative drugs. The pipeline currently under research involves tumors, autoimmune diseases, respiratory diseases and other fields.

Venture Incubate Biotech is led by a team of scientists and works with professional biomedical investment institutions to create a unique innovative drug incubation platform in China. The company has gathered industry elites and formed an innovation team covering the whole process of innovative drug research and development, intellectual property protection, CMC, drug registration declaration, drug clinical research, business development and so on.

The company is located in Suzhou Industrial Park Biomedical Industrial Park, the company was founded at the beginning of the angel round investment of tens of millions of yuan, and has thousands of square meters of office space and R & D platform.

At present, the company has completed more than ten target studies of First-in-class drugs, five of the projects launched in the first phase have entered the candidate molecular screening optimization stage, and one has completed the in vitro and in vitro pharmacodynamic evaluation, and is expected to submit a Sino-US IND application next year.